Partners
maximizing
global opportunities
PARTNERSHIPS
As we continue to fully explore the broad potential of our platform and candidates, we’ve engaged in both industry and academic collaboration and transactions to maximize our opportunities.
In September 2023, we announced a strategic collaboration with CTMC, a joint venture between National Resilience, Inc. and MD Anderson Cancer Center, to provide full process development and manufacturing support for and expedite the development of our two lead engineered tumor-infiltrating lymphocyte eTIL® programs, KSQ-001EX and KSQ-004EX, both of which are advancing toward clinical studies for the treatment of solid tumors.
In January 2021, we announced our broad strategic collaboration with Takeda to research, develop and commercialize novel immune-based therapies for cancer. Under the agreement, KSQ granted Takeda an exclusive, worldwide, royalty-bearing license to develop, manufacture and commercialize cell and non-cell therapy products that modulate targets identified using KSQ’s CRISPRomics® technology. The deal focused on the discovery of novel NK cell and T cell-based targets, and it was expanded in May 2023 to include work on tumor-intrinsic targets. KSQ has received upfront payments, investments, and milestones and is eligible for additional future payments if all milestones are met, plus royalties on potential net sales of any commercial product resulting from the collaboration.
In January 2023, we announced that Ono Pharmaceutical Co., Ltd. had acquired multiple of our research-stage DNA damage response (DDR) programs identified using our CRISPRomics® platform technology, all novel with the potential to become first-in-class therapies. Under the terms of the agreement, ONO provided KSQ a double-digit million upfront payment with additional near-term milestone payments expected and potential royalties based on any future net sales achieved.
ACADEMIC PARTNERSHIPS
In addition to our corporate partnerships, we also collaborate with top-tier academic institutions.